Why Celgene Is Poised to Keep Popping

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene has earned a respected four-star ranking.

With that in mind, let's take a closer look at Celgene, and see what CAPS investors are saying about the stock right now.

Celgene facts

Headquarters (founded)

Summit, N.J. (1980)

Market Cap

$41.8 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$5.5 billion

Management

Chairman/CEO Robert Hugin

CFO Jacqualyn Fouse

Return on Equity (average, past 3 years)

21.9%

Cash / Debt

$3.8 billion / $3.1 billion

Competitors

Johnson & Johnson

Pfizer

Amgen

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 1,594 members who have rated Celgene believe the stock will outperform the S&P 500 going forward.

Earlier this month, one of those Fools, EpikurFool, succinctly summed up the Celgene bull case for our community:

Of course, that short pitch doesn't even come close to telling the entire story for Celgene. You're in luck, though. The Fool's brand-new premium report on Celgene looks at all sides of one of the most compelling biotechnology companies in the world. You can grab your copy, which comes with free updates for 12 months.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.